Clinical trials: Hematopoietic Stem Cells
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL.
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Trial name
- HEM-iSMART A (NCT05740449)
- Testing
- Decitabine, Venetoclax, Navitoclax
- Where
- Netherlands
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Lymphoma
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00003143
- Testing
- Amifostine, DHAP
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Chemotherapy Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
CART22 Alone or in Combination With huCART19 for ALL
This is a single center, open-label, phase 1 study to determine the safety and feasibility of infusing CART22-65s with or without huCART19 after administration of lymphodepleting chemotherapy in adult patients with relapsed or…
- Trial name
- NCT03620058
- Testing
- CART22-65s cells, huCART19 Cells
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Pennsylvania
Thrombocytopenia, Stem Cell Transplant Complications
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT
In this study, investigators aim to evaluate the efficacy of avatrombopag in thrombocytopenic patients after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) through a prospective, multi-center, double-blinded…
- Trial name
- Haplo-HSCT (NCT06202625)
- Testing
- avatrombopag
- Where
- 14 sites in China
- Volunteers
- 142 people
- Sponsor
- Peking University People's Hospital
B-NHL, B-Non Hodgkin Lymphoma
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured.
- Conditions
- B-NHL, B-Non Hodgkin Lymphoma, Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT05442515
- Testing
- CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Background: Chronic lymphocytic leukemia (CLL),small lymphocytic lymphoma (SLL) and B-cell acute lymphoblastic leukemia or lymphoma (ALL) are blood cancers that affect certain white blood cells.
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic, B-Cell Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT06364423
- Testing
- Autologous HuCD19 ( Anti-CD19)CAR T cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- National Cancer Institute (NCI)
Sickle Cell Disease
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
This study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease.
- Trial name
- Restore (NCT04819841)
- Testing
- nula-cel Drug Product
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Kamau Therapeutics
Leukemia
Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
RATIONALE: Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of panobinostat and to see how well it works in…
- Trial name
- NCT00723203
- Testing
- panobinostat, gene expression analysis, reverse transcriptase-polymerase chain reaction
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
CD34+ Transplants for Myeloid Malignancies
This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in less complications for patients undergoing transplant for treatment of a blood malignancy…
- Trial name
- NCT05565105
- Testing
- Busulfan, Melphalan, Fludarabine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Guenther Koehne
Cardiomyopathy, Dilated
Autologous Stem Cells in Pediatric Patients With Dilated Cardiomyopathy
The purpose of this study is to determine whether an autologous stem cell infusion through catheterism is safe and effective in the treatment of pediatric dilated cardiomyopathy. Process: 1.
- Trial name
- NCT01504594
- Testing
- Intracoronary autologous stem cell infusion
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Fungal Infection, Bacterial Infection
Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients
The safety and tolerability of hLF 1-11 given in multiple doses has to be established first in HSCT recipients who are at risk of developing, but have not yet developed, infectious complications due to invasive fungal or…
- Trial name
- NCT00430469
- Testing
- human lactoferrin (hLF1-11)
- Where
- Netherlands
- Sponsor
- AM-Pharma
Chronic Myeloproliferative Disorders, Leukemia
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00290641
- Testing
- filgrastim, graft-versus-tumor induction therapy, cyclophosphamide
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Granuloma, Granulomatous Disease, Chronic
Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes
The research goal of this study is to obtain CD34+ hematopoietic stem cells (HSC) from peripheral blood and/or bone marrow, and Mononuclear Cells (lymphocytes and monocytes), and granulocytes (grans) from peripheral blood that…
- Conditions
- Granuloma, Granulomatous Disease, Chronic, Leukocyte Disease, Genetic Disease, X-Linked
- Trial name
- NCT00001405
- Where
- United States
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Leukemia, Lymphoma
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
RATIONALE: Biological therapy using growth factors may be effective in reducing side effects in patients who have hematologic cancer and are receiving radiation therapy, chemotherapy, and peripheral stem cell transplantation.
- Conditions
- Leukemia, Lymphoma, Oral Complications
- Trial name
- NCT00004061
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Childhood ALL
Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP
The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in…
- Trial name
- LALGFA2019 (NCT04794296)
- Where
- 3 sites in Côte d’Ivoire, Guinea and 1 more
- Volunteers
- 500 people
- Sponsor
- French Africa Pediatric Oncology Group
Obesity, Stem Cell Transplant
Behavioral Weight Loss Intervention Utilizing Mobile Health Technology in Hematopoietic Stem Cell Transplant Patients
Pilot study enrolling obese post HSCT (hematopoietic stem cell transplantation) patients at the hematology/oncology clinic at the Mattel Children's Hospital, University of California, Los Angeles.
- Trial name
- NCT04997473
- Testing
- W8L2G mobile health (mHealth) app
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Mature B-Cell
Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL
This is a pilot study to demonstrate that the modified LMB-89 treatment regimen for children with newly diagnosed small noncleaved cell NHL, large cell NHL (B-cell), and B-cell acute lymphoblastic leukemia can be delivered in…
- Trial name
- NCT00187161
- Testing
- Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- St. Jude Children's Research Hospital
Hematopoietic and Lymphoid Cell Neoplasm
Fecal Microbiota Transplantation for Steroid Resistant/Dependent Acute GI GVHD
The purpose of this study is to evaluate the efficacy and safety of fecal microbiome transplantation in patients with steroid resistant/dependent acute gastrointestinal graft-versus-host disease (GVHD).
- Trial name
- FEMITGIGVHD (NCT03812705)
- Testing
- fecal microbiome transplantation
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Acute Lymphoblastic Leukemia (ALL)
Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia
This was a Phase 2, international, multicenter, open-label, single-arm trial evaluating Marqibo (VSLI) in adult subjects with: 1) Ph- ALL or lymphoblastic lymphoma in second or greater relapse; or 2) Ph- ALL or lymphoblastic…
- Trial name
- NCT00495079
- Testing
- Marqibo® (vincristine sulfate liposomes injection)
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 65 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Acute Myeloid Leukemia
A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients
This study will examine the safety and anti-leukemic profile of SGN-CD33A (vadastuximab talirine) in patients with relapsed chemo-resistant AML, who are given vadastuximab talirine in sequence with standard treatments before a…
- Trial name
- NCT02614560
- Testing
- Fludarabine, Melphalan, vadastuximab talirine
- Where
- 11 sites in United States
- Volunteers
- 14 people
- Sponsor
- Seagen Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.